Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product.
Markets on alert for changes to runoff of Fed’s balance sheet
Financial markets are not just focused on what the Federal Reserve says about the future path of interest rates on Wednesday. The markets are…
